Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatm...
Guardado en:
Autores principales: | Naglaa El-Gendy, Fathiya EL-Raey, Sherif Nassib, Noha Elsadany |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Al-Azhar University, Faculty of Medicine (Damietta)
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d77cf999ebbc437a90bbcf7c9a2894ed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein D, et al.
Publicado: (2019) -
Combination of Multiple Hemodialysis Modes: Better Treatment Options for Patients Under Maintenance Hemodialysis
por: Zhang ZY, et al.
Publicado: (2021) -
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
por: Hussaini T
Publicado: (2016) -
Hemodialysis international
Publicado: (2000) -
Components of quality of life in hemodialysis patients from family caregivers’ perspective: a qualitative study
por: Sima Sadat Hejazi, et al.
Publicado: (2021)